Home > News > Nanotechnology Institute Signs GlaxoSmithKline
April 1st, 2004
Nanotechnology Institute Signs GlaxoSmithKline
Abstract:
The Nanotechnology Institute (NTI), a comprehensive model for the development of nanotechnology-driven, real-world applications, has signed GlaxoSmithKline (GSK) as a corporate member. This partnership reflects the NTI's efforts to commercialize the basic research done through the Institute's four core research teams. It also matches GSK's efforts to identify technologies that enable new product and research methodologies.
Source:
PrimeZone
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||